
## Virginia Merino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8244166/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	In vitro skin penetration of bronidox, bronopol and formaldehyde from cosmetics. Regulatory Toxicology and Pharmacology, 2021, 122, 104888.	1.3	9
2	Development, characterization, and ex vivo evaluation of an insert for the ocular administration of progesterone. International Journal of Pharmaceutics, 2021, 606, 120921.	2.6	8
3	Current profile controlled transdermal delivery of pramipexole from an iontophoretic patch system in vitro and in vivo. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 166, 175-181.	2.0	4
4	3D Printing of Temporary Prostheses for Controlled-Release of Drugs: Design, Physical Characterization and Preliminary Studies. Pharmaceuticals, 2021, 14, 1240.	1.7	2
5	Global testing of a consensus solubility assessment to enhance robustness of the WHO biopharmaceutical classification system. ADMET and DMPK, 2021, 9, 23-39.	1.1	7
6	New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy. International Journal of Molecular Sciences, 2020, 21, 6502.	1.8	43
7	Influence of Inter- and Intra-Batch Variability on the Sample Size Required for Demonstration of Equivalent Microstructure of Semisolid Dosage Forms. Pharmaceutics, 2020, 12, 1159.	2.0	8
8	Candesartan Cilexetil In Vitro–In Vivo Correlation: Predictive Dissolution as a Development Tool. Pharmaceutics, 2020, 12, 633.	2.0	17
9	Statistical Methods for Quality Equivalence of Topical Products. 0.5 mg/g Betamethasone Ointment as a Case-Study. Pharmaceutics, 2020, 12, 318.	2.0	6
10	Assessment of the Inter-Batch Variability of Microstructure Parameters in Topical Semisolids and Impact on the Demonstration of Equivalence. Pharmaceutics, 2019, 11, 503.	2.0	17
11	Relationship between rheological properties, in vitro release and in vivo equivalency of topical formulations of diclofenac. International Journal of Pharmaceutics, 2019, 572, 118755.	2.6	15
12	Controlled Iontophoretic Delivery <i>in Vitro</i> and <i>in Vivo</i> of ARN14140—A Multitarget Compound for Alzheimer's Disease. Molecular Pharmaceutics, 2019, 16, 3460-3468.	2.3	19
13	Development of antibiotic loaded biodegradable matrices to prevent superficial infections associated to total knee arthroplasty. Colloids and Surfaces B: Biointerfaces, 2019, 181, 1-5.	2.5	9
14	Double Drug Delivery Using Capped Mesoporous Silica Microparticles for the Effective Treatment of Inflammatory Bowel Disease. Molecular Pharmaceutics, 2019, 16, 2418-2429.	2.3	18
15	Efficacy of budesonide-loaded mesoporous silica microparticles capped with a bulky azo derivative in rats with TNBS-induced colitis. International Journal of Pharmaceutics, 2019, 561, 93-101.	2.6	12
16	Covalently crosslinked organophosphorous derivatives-chitosan hydrogel as a drug delivery system for oral administration of camptothecin. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 136, 174-183.	2.0	45
17	lonic Hydrogel Based on Chitosan Cross-Linked with 6-Phosphogluconic Trisodium Salt as a Drug Delivery System. Biomacromolecules, 2018, 19, 1294-1304.	2.6	41
18	A preclinical study to model taurine pharmokinetics in the undernourished rat. British Journal of Nutrition, 2018, 119, 826-835.	1.2	2

#	Article	IF	CITATIONS
19	Simultaneous controlled iontophoretic delivery of pramipexole and rasagiline in vitro and in vivo: Transdermal polypharmacy to treat Parkinson's disease. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 204-212.	2.0	23
20	Long-Circulating Hyaluronan-Based Nanohydrogels as Carriers of Hydrophobic Drugs. Pharmaceutics, 2018, 10, 213.	2.0	4
21	Influence of Chemical Enhancers and Iontophoresis on the In Vitro Transdermal Permeation of Propranolol: Evaluation by Dermatopharmacokinetics. Pharmaceutics, 2018, 10, 265.	2.0	19
22	Investigation of Different Iontophoretic Currents Profiles for Short-Term Applications in Cosmetics. Pharmaceutics, 2018, 10, 266.	2.0	5
23	Functional Magnetic Mesoporous Silica Microparticles Capped with an Azo-Derivative: A Promising Colon Drug Delivery Device. Molecules, 2018, 23, 375.	1.7	11
24	Smart gated magnetic silica mesoporous particles for targeted colon drug delivery: New approaches for inflammatory bowel diseases treatment. Journal of Controlled Release, 2018, 281, 58-69.	4.8	39
25	Mesoporous silica microparticles gated with a bulky azo derivative for the controlled release of dyes/drugs in colon. Royal Society Open Science, 2018, 5, 180873.	1.1	6
26	Levofloxacin effect on erlotinib absorption. Evaluation of the interaction in undernutrition situations through population pharmacokinetic analysis in rats. Biopharmaceutics and Drug Disposition, 2017, 38, 315-325.	1.1	1
27	Iontophoresis for Therapeutic Drug Delivery and Non-invasive Sampling Applications. , 2017, , 77-101.		1
28	Bioactivity of Ceftazidime and Fluconazole Included in Polymethyl Methacrylate Bone Cement for Use in Arthroplasty. Journal of Arthroplasty, 2017, 32, 3126-3133.e1.	1.5	12
29	Impact of Undernutrition on the Pharmacokinetics and Pharmacodynamics of Anticancer Drugs: A Literature Review. Nutrition and Cancer, 2017, 69, 555-563.	0.9	11
30	Transdermal therapeutic systems for memantine delivery. Comparison of passive and iontophoretic transport. International Journal of Pharmaceutics, 2017, 517, 104-111.	2.6	14
31	Antibioticâ€loaded Bone Cement as Prophylaxis in Total Joint Replacement. Orthopaedic Surgery, 2017, 9, 331-341.	0.7	33
32	Development and In Vitro Evaluation of Lyotropic Liquid Crystals for the Controlled Release of Dexamethasone. Polymers, 2017, 9, 330.	2.0	19
33	A UHPLC-UV Method to Quantify Skin Deposition and Transdermal Permeation of Tizanidine Hydrochloride. Journal of Chromatographic Science, 2016, 54, 790-795.	0.7	3
34	Controlled transdermal iontophoresis for poly-pharmacotherapy: Simultaneous delivery of granisetron, metoclopramide and dexamethasone sodium phosphate in vitro and in vivo. European Journal of Pharmaceutical Sciences, 2016, 85, 31-38.	1.9	29
35	Impact of nutritional status on the pharmacokinetics of erlotinib in rats. Biopharmaceutics and Drug Disposition, 2015, 36, 373-384.	1.1	3
36	Synthesis of 3-azabicyclo[3.2.2]nonanes and their antiprotozoal activities. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1390-1393.	1.0	14

#	Article	IF	CITATIONS
37	Therapeutic efficacy of quercetin enzyme-responsive nanovesicles for the treatment of experimental colitis in rats. Acta Biomaterialia, 2015, 13, 216-227.	4.1	74
38	Development of antimigraine transdermal delivery systems of pizotifen malate. International Journal of Pharmaceutics, 2015, 492, 223-232.	2.6	14
39	Study of the Influence of Bone Cement Type and Mixing Method on the Bioactivity and the Elution Kinetics of Ciprofloxacin. Journal of Arthroplasty, 2015, 30, 1243-1249.	1.5	18
40	Variability of permeability estimation from different protocols of subculture and transport experiments in cell monolayers. Journal of Pharmacological and Toxicological Methods, 2015, 71, 21-32.	0.3	31
41	Controlled iontophoretic delivery of pramipexole: Electrotransport kinetics in vitro and in vivo. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 56-63.	2.0	27
42	Polymeric nanospheres as strategy to increase the amount of triclosan retained in the skin: passive diffusion vs. iontophoresis. Journal of Microencapsulation, 2013, 30, 72-80.	1.2	18
43	Controlled Iontophoretic Transport of Huperzine A across Skin <i>in Vitro</i> and <i>in Vivo</i> : Effect of Delivery Conditions and Comparison of Pharmacokinetic Models. Molecular Pharmaceutics, 2013, 10, 4322-4329.	2.3	15
44	Improving Oral Bioavailability and Pharmacokinetics of Liposomal Metformin by Glycerolphosphate–Chitosan Microcomplexation. AAPS PharmSciTech, 2013, 14, 485-496.	1.5	41
45	Evaluation of Percutaneous Absorption of Esculetin: Effect of Chemical Enhancers. Planta Medica, 2013, 79, 131-136.	0.7	2
46	High-Performance Liquid Chromatographic Ultraviolet Determination of Memantine Hydrochloride afterIn VitroTransdermal Diffusion Studies. Journal of Chemistry, 2013, 2013, 1-7.	0.9	4
47	Hydroxypropylmethylcellulose films for the ophthalmic delivery of diclofenac sodium. Journal of Pharmacy and Pharmacology, 2012, 65, 193-200.	1.2	27
48	Transdermal absorption of memantine – Effect of chemical enhancers, iontophoresis, and role of enhancer lipophilicity. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 82, 164-170.	2.0	32
49	HPLCâ€UV analytical method for determination of pizotifen after <i>in vitro</i> transdermal diffusion studies. Biomedical Chromatography, 2012, 26, 769-774.	0.8	2
50	Design, characterization and in vitro evaluation of 5-aminosalicylic acid loaded N-succinyl-chitosan microparticles for colon specific delivery. Colloids and Surfaces B: Biointerfaces, 2012, 94, 199-205.	2.5	69
51	Chemical Enhancers. , 2012, , 23-40.		0
52	Transdermal nortriptyline hydrocloride patch formulated within a chitosan matrix intended to be used for smoking cessation. Pharmaceutical Development and Technology, 2011, 16, 162-169.	1.1	18
53	In Situ Study of the Effect of Naringin, Talinolol and Protein-Energy Undernutrition on Intestinal Absorption of Saquinavir in Rats. Basic and Clinical Pharmacology and Toxicology, 2011, 109, 245-252.	1.2	3
54	N-Succinyl-chitosan systems for 5-aminosalicylic acid colon delivery: In vivo study with TNBS-induced colitis model in rats. International Journal of Pharmaceutics, 2011, 416, 145-54.	2.6	55

#	Article	IF	CITATIONS
55	Effect of iontophoresis on in vitro transdermal absorption of almotriptan. International Journal of Pharmaceutics, 2011, 416, 189-194.	2.6	32
56	Influence of polyunsaturated fatty acids on Cortisol transport through MDCK and MDCK-MDR1 cells as blood–brain barrier in vitro model. European Journal of Pharmaceutical Sciences, 2011, 42, 290-299.	1.9	29
57	Elastic vesicles of sumatriptan succinate for transdermal administration: characterization and <i>in vitro</i> permeation studies. Journal of Liposome Research, 2011, 21, 55-59.	1.5	12
58	Enhancement of nortriptyline penetration through human epidermis: influence of chemical enhancers and iontophoresis. Journal of Pharmacy and Pharmacology, 2010, 60, 415-420.	1.2	14
59	Using transdermal iontophoresis to increase granisetron delivery across skin in vitro and in vivo: Effect of experimental conditions and a comparison with other enhancement strategies. European Journal of Pharmaceutical Sciences, 2010, 39, 387-393.	1.9	32
60	Comparing metoclopramide electrotransport kinetics in vitro and in vivo. European Journal of Pharmaceutical Sciences, 2010, 41, 353-359.	1.9	8
61	Transdermal iontophoresis of dexamethasone sodium phosphate in vitro and in vivo: Effect of experimental parameters and skin type on drug stability and transport kinetics. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 75, 173-178.	2.0	43
62	Combined strategies for enhancing the transdermal absorption of midazolam through human skin. Journal of Pharmacy and Pharmacology, 2010, 62, 1096-1102.	1.2	11
63	Development and evaluation of occlusive systems employing polyvinyl alcohol for transdermal delivery of sumatriptan succinate. Drug Delivery, 2010, 17, 83-91.	2.5	10
64	Transdermal Iontophoresis. , 2010, , 41-52.		2
65	The Dopamine Uptake Inhibitor 3α-[bis(4′-fluorophenyl)metoxy]-tropane Reduces Cocaine-Induced Early-Gene Expression, Locomotor Activity, and Conditioned Reward. Neuropsychopharmacology, 2009, 34, 2497-2507.	2.8	29
66	Unique pharmacology of KAR-2, a potential anti-cancer agent: Absorption modelling and selective mitotic spindle targeting. European Journal of Pharmaceutical Sciences, 2009, 36, 11-19.	1.9	8
67	A dopamine transport inhibitor with markedly low abuse liability suppresses cocaine self-administration in the rat. Psychopharmacology, 2009, 207, 281-289.	1.5	31
68	The Use of lontophoresis in the Administration of Nicotine and New Non-Nicotine Drugs through the Skin for Smoking Cessation. Current Drug Discovery Technologies, 2009, 6, 171-185.	0.6	28
69	Sumatriptan Succinate Transdermal Delivery Systems for The Treatment of Migraine. Journal of Pharmaceutical Sciences, 2008, 97, 2102-2109.	1.6	24
70	Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2008, 366, 3599-3617.	1.6	13
71	Population modelling to describe pharmacokinetics of amiodarone in rats: Relevance of plasma protein and tissue depot binding. European Journal of Pharmaceutical Sciences, 2007, 30, 190-197.	1.9	8
72	Mathematical modelling of in situ and in vitro efflux of ciprofloxacin and grepafloxacin. International Journal of Pharmaceutics, 2006, 307, 33-41.	2.6	20

#	Article	IF	CITATIONS
73	Combination strategies for enhancing transdermal absorption of sumatriptan through skin. International Journal of Pharmaceutics, 2006, 323, 125-130.	2.6	30
74	Bioadhesive monolayer film for the in vitro transdermal delivery of sumatriptan. Journal of Pharmaceutical Sciences, 2006, 95, 1561-1569.	1.6	29
75	High-performance liquid chromatographic determination of sumatriptan after in vitro transdermal diffusion studies. Journal of Pharmaceutical and Biomedical Analysis, 2005, 37, 621-626.	1.4	31
76	Iontophoretic Transdermal Delivery of Sumatriptan: Effect of Current Density and Ionic Strength. Journal of Pharmaceutical Sciences, 2005, 94, 2183-2186.	1.6	21
77	Effect of chemical enhancers on the in vitro percutaneous absorption of sumatriptan succinate. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 61, 50-55.	2.0	86
78	PAMPA—a drug absorption in vitro model. European Journal of Pharmaceutical Sciences, 2004, 21, 429-441.	1.9	187
79	Relevance of Multidrug Resistance Proteins on the Clinical Efficacy of Cancer Therapy. Current Drug Delivery, 2004, 1, 203-212.	0.8	27
80	Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: in vitro and in situ inhibition studies. European Journal of Pharmaceutics and Biopharmaceutics, 2003, 55, 241-246.	2.0	32
81	Kinetic Modeling of Triamterene Intestinal Absorption and its Inhibition by Folic Acid and Methotrexate. Journal of Drug Targeting, 2003, 11, 215-223.	2.1	9
82	Intrinsic Absolute Bioavailability Prediction in Rats Based on In Situ Absorption Rate Constants and/or In Vitro Partition Coefficients: 6â€Fluoroquinolones. Journal of Pharmaceutical Sciences, 2000, 89, 1395-1403.	1.6	28
83	Iontophoresis: electrorepulsion and electroosmosis. Journal of Controlled Release, 2000, 64, 129-132.	4.8	270
84	Validation of a biophysical drug absorption model by the PATQSAR system. Journal of Pharmaceutical Sciences, 1999, 88, 398-405.	1.6	39
85	Electrorepulsion versus electroosmosis: effect of pH on the iontophoretic flux of 5-fluorouracil. Pharmaceutical Research, 1999, 16, 758-761.	1.7	73
86	Noninvasive sampling of phenylalanine by reverse iontophoresis. Journal of Controlled Release, 1999, 61, 65-69.	4.8	54
87	Pharmacokinetics, bioavailability and absorption of flumequine in the rat. European Journal of Pharmaceutics and Biopharmaceutics, 1999, 48, 253-258.	2.0	20
88	TRANSDERMAL DRUG DELIVERY. Dermatologic Clinics, 1998, 16, 289-299.	1.0	55
89	Transdermal and Skin-Targeted Drug Delivery. Journal of Cutaneous Medicine and Surgery, 1997, 2, 108-119.	0.6	2
90	Transdermal therapy and diagnosis by iontophoresis. Trends in Biotechnology, 1997, 15, 288-290.	4.9	59

#	Article	IF	CITATIONS
91	Biophysical Models as an Approach To Study Passive Absorption in Drug Development: 6-Fluoroquinolones. Journal of Pharmaceutical Sciences, 1995, 84, 777-782.	1.6	32
92	Compared effects of synthetic and natural bile acid surfactant on xenobiotic absorption. II. Studies with sodium glycocholate to confirm a hypothesis. International Journal of Pharmaceutics, 1994, 101, 209-217.	2.6	12
93	Compared effects of synthetic and natural bile acid surfactants on xenobiotic absorption. III. studies with mixed micelles. International Journal of Pharmaceutics, 1994, 107, 159-166.	2.6	7